Renin Inhibitor Market Size & Share, by Product Type (150mg/Tablet & 300mg/Tablet) and By Application (Below 45, 46-55, 56-65 & Above 66) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2633
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

The market is projected to witness a robust growth owing to the rising awareness about hypertension with growing predominance, fixed-dose blending therapies, and escalated epidemic proportions of hypertension. According to the World Health Organization, around 1.13 billion people worldwide are suffering from hypertension, most (two-thirds) living in low- and middle-income countries. Moreover, irregular lifestyle with food habits, changing lifestyle, aging regardless of demography, and supplemented stress level coupled with rising research and development for the modern drugs also supporting the growth of the market. However, side effects such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization are estimated to hinder the growth of the global market over the forecast period.


Get more information on this report: Request Free Sample PDF

Renin Inhibitor Sector: Growth Drivers and Challenges

Growth Drivers

Frequency of Cardiovascular Diseases Among the Geriatric Population

The renin inhibitor market is estimated to observe a significant growth on account of the frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications. Additionally, an individual who suffers from hypertension is very susceptible to other complications such as aneurysm and heart failure. Thus, requires early diagnosis as well as management by using renin inhibitor drugs.

Rampant Research and Development for the Antihypertensive Drugs Driving the Global Market

An upsurge in research related to antihypertensive drugs in developing economies coupled with pulmonary hypertensive practices offering training programs for people, a high predominance of incessant illness, initiatives are taken by the government and the growing commonness of hypertension in youth population in emerging economies are anticipated to fuel the growth of renin inhibitor over the forecast period., i.e. 2020-2028.

Challenges

Side Effects of Renin Inhibitors

Growth of renin inhibitor is expected to be hampered by the side effects of drugs such as cough, diarrhea, nervousness, constipation, dizziness, weakness, and increased risk of genericization coupled with recent patent expirations.

Renin Inhibitor Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Renin Inhibitor Segmentation

The renin inhibitor market is segmented by product type & by application, out of which, the age above 66 segment of the application sector is anticipated to hold leading shares in the market on account of rising cardiovascular diseases and hypertension cases among this segment. According to the National Centre for Health Statistics. From 2015 to 2016, the prevalence of hypertension was 29.0% and increased with age: age group 18–39, 7.5%; 40–59, 33.2%; and 60 and over, 63.1%. On the contrary, 300mg/tablet segment of the product type sector is estimated to witness modest growth over the forecast period owing to the treatment of high blood pressure by relaxing blood vessels for a better circulation of the blood.

Our in-depth analysis of the global market includes the following segments:

           By Product Type

  • 150mg/Tablet
  • 300mg/Tablet

             By Application

  • Below 45
  • 46-55
  • 55-65
  • Above 66

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Renin Inhibitor Industry - Regional Synopsis

Based on geographically, the renin inhibitor market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

The market in North America industry is set to account for largest revenue share by 2036, on account of a rise in the prevalence of hypertension and chronic kidney disorders. Conversely, the presence of major companies propels the market growth in the North America region. On the contrary, the Asia-Pacific region is anticipated to witness high growth in the global renin inhibitor market over the forecast period owing to the high incidences of cardiovascular diseases, government initiatives taken for the healthcare sector, and high population pool.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Renin Inhibitor Landscape

    • Johnson & Johnson
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer
    • Bio-Rad Laboratories Inc.
    • Sanofi
    • Lupin
    • Merck & Co.
    • Astra Zeneca
    • Daiichi Sankyo
    • Novartis
    • Boehringer Ingelheim International GmbH

In the News

  • September 2020: Aliskiren becomes the first direct renin inhibitor to available in the UK launched by Novartis and is licensed either as monotherapy or in combination with other antihypertensives.

Author Credits:  Radhika Pawar


  • Report ID: 2633
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

North America industry is set to account for largest revenue share by 2036, on account of a rise in the prevalence of hypertension and chronic kidney disorders.

The major players in the market are Johnson & Johnson, Pfizer, Bio-Rad Laboratories Inc., Sanofi, Lupin, Merck & Co., Astra Zeneca, Daiichi Sankyo, Novartis, Boehringer Ingelheim International GmbH, and others.
Renin Inhibitor Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample